Some aspects of the drug therapy of type 2 diabetes mellitus in overweight patients

Main Article Content

S.V. Jargin


This is a mini-review of recent publications on hypoglycemic drugs applicable to the treatment of type 2 diabetes mellitus in overweight patients. The article discusses the follo­wing topics: the influence of medications on body weight, function of pancreatic beta-cells, indications for the intensive glycemic control and medication costs. Glucagon-like peptide-1 receptor agonists stimulate insulin secretion, slow down gastric emptying, cause satiety and reduce food intake, contributing to the weight loss. The sodium glucose cotransporter 2 inhibitors suppress the renal glucose reabsorption, lower blood pressure and contribute to a reduction of body weight. A body weight reduction should be awaited also from inhibitors of intestinal alpha-glucosidase. Hypoglycemic effects of the two latter drug classes are unrelated to the stimulation of insulin secretion by beta cells. It is known that the secretory function of pancreatic islets can be exhausted by a prolonged stimulation. In conclusion, the goals of glycemic control need to be individualized based on the age, prognosis, presence of cardiovascular disease, and risk of hypoglycemia. Approp­riate management of hypertension, dyslipidemia, and other cardiovascular risk factors are of importance for the prevention of complications in type 2 diabetes mellitus.

Article Details

How to Cite
Jargin, S. “Some Aspects of the Drug Therapy of Type 2 Diabetes Mellitus in Overweight Patients”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 15, no. 5, Oct. 2019, pp. 410-8, doi:10.22141/2224-0721.15.5.2019.180046.
Literature Review


American Diabetes Association. Standards of medical care in diabetes – 2018. Diabetes Care. 2018 Jan;41(Suppl 1). doi: 10.2337/dc18-Sint01.

Dedov II, Shestakova MV. Type 2 diabetes mellitus: from theory to practice. Moscow: MIA; 2016. (in Russian).

Dreval AB, Misnikova IV, Starostina EG, et al. Practice of Diabetology. Moscow: GEOTAR-Media; 2018. (in Russian).

Dawed AY, Zhou K, van Leeuwen N, et al. Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by SLC29A4) and Organic Cation Transporter 1 (OCT1) (Encoded by SLC22A1) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT Study. Diabetes Care. 2019 Jun;42(6):1027-1033. doi: 10.2337/dc18-2182.

Korpacheva-Zinych OV, Kushnariova NM, Kovalchuk AV, et al. In tune with the world trends: clinical aspects of liraglutide use in combination with insulin in patients with diabetes mellitus. Mìžnarodnij endokrinologìčnij žurnal. 2016;(79):35-43. doi: 10.22141/2224-0721.7.79.2016.86417.

Fujita Y, Inagaki N. Metformin: New Preparations and Nonglycemic Benefits. Curr Diab Rep. 2017 Jan;17(1):5. doi: 10.1007/s11892-017-0829-8.

Hanefeld M. Pioglitazone and sulfonylureas: effectively treating type 2 diabetes. Int J Clin Pract Suppl. 2007 Jun;(153):20-7. doi: 10.1111/j.1742-1241.2007.01361.x.

Dedov II, Shestakova MV, Mayorov AY, et al. Standards of specialized diabetes care - 8th Edition. Diabetes Mellitus. 2017;20(Suppl 1):1-112. doi: 10.14341/DM20171S8. (in Russian).

Iglesias P, Heras M, Díez JJ. Diabetes mellitus and kidney disease in the elderly. Nefrologia. 2014 May 21;34(3):285-92. doi: 10.3265/Nefrologia.pre2014.Feb.12319.

Schernthaner G, Ritz E, Schernthaner GH. Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly? Nephrol Dial Transplant. 2010 Jul;25(7):2044-7. doi: 10.1093/ndt/gfq199.

Hasslacher C; Multinational Repaglinide Renal Study Group. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care. 2003 Mar;26(3):886-91. doi: 10.2337/diacare.26.3.886.

Ioannidis I. Diabetes treatment in patients with renal disease: Is the landscape clear enough? World J Diabetes. 2014 Oct 15;5(5):651-8. doi: 10.4239/wjd.v5.i5.651.

Davies M, Chatterjee S, Khunti K. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clin Pharmacol. 2016 Jun 23;8:61-81. doi: 10.2147/CPAA.S82008.

Liao HW, Saver JL, Wu YL, Chen TH, Lee M, Ovbiagele B. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open. 2017 Jan 5;7(1):e013927. doi: 10.1136/bmjopen-2016-013927.

Pfeiffer AFH, Klein HH. The treatment of type 2 diabetes. Dtsch Arztebl Int. 2014 Jan 31;111(5):69-81; quiz 82. doi: 10.3238/arztebl.2014.0069.

Di Lullo L, Mangano M, Ronco C, et al. The treatment of type 2 diabetes mellitus in patients with chronic kidney disease: What to expect from new oral hypoglycemic agents. Diabetes Metab Syndr. 2017 Nov;11 Suppl 1:S295-S305. doi: 10.1016/j.dsx.2017.03.005.

Monami M, Dicembrini I, Nreu B, Andreozzi F, Sesti G, Mannucci E. Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials. Acta Diabetol. 2017 Dec;54(12):1101-1114. doi: 10.1007/s00592-017-1054-2.

Anderson JE, Thieu VT, Boye KS, Hietpas RT, Garcia-Perez LE. Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers. Postgrad Med. 2016 Nov;128(8):810-821. doi: 10.1080/00325481.2016.1218260.

Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev. 2016 Nov;32(8):776-790. doi: 10.1002/dmrr.2810.

Tuchscherer RM, Thompson AM, Trujillo JM. Semaglutide: the newest once-weekly GLP-1 RA for type 2 diabetes. Ann Pharmacother. 2018 Dec;52(12):1224-1232. doi: 10.1177/1060028018784583.

Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019 Apr 16;321(15):1466-1480. doi: 10.1001/jama.2019.2942.

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827.

Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015 Dec 3;373(23):2247-57. doi: 10.1056/NEJMoa1509225.

Bosi E. Pharmacotherapy of type 2 diabetes: last advances and ways of their implementation into clinical practice. Effective Pharmacotherapy. 2016;(12):36-38. (in Russian).

Romantsova TI. Glucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity. Obesity and metabolism. 2018;15(1):3-11. (in Russian).

Apovian CM, Okemah J, O’Neil PM. Body weight considerations in the management of type 2 diabetes. Adv Ther. 2019 Jan;36(1):44-58. doi: 10.1007/s12325-018-0824-8.

Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2016 Mar;18(3):203-16. doi: 10.1111/dom.12591.

Garber AJ. Incretin effects on β-cell function, replication, and mass: the human perspective. Diabetes Care. 2011 May;34 Suppl 2:S258-63. doi: 10.2337/dc11-s230. doi: 10.2337/dc11-s230.

Talbot J, Joly E, Prentki M, Buteau J. β-Arrestin1-mediated recruitment of c-Src underlies the proliferative action of glucagon-like peptide-1 in pancreatic β INS832/13 cells. Mol Cell Endocrinol. 2012 Nov 25;364(1-2):65-70. doi: 10.1016/j.mce.2012.08.010.

Fleming A, Rosenberg L. Prospects and challenges for islet regeneration as a treatment for diabetes: a review of islet neogenesis associated protein. J Diabetes Sci Technol. 2007 Mar;1(2):231-44. doi: 10.1177/193229680700100214.

Inaba W, Mizukami H, Kamata K, Takahashi K, Tsuboi K, Yagihashi S. Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats. Eur J Pharmacol. 2012 Sep 15;691(1-3):297-306. doi: 10.1016/j.ejphar.2012.07.030.

Mu J, Petrov A, Eiermann GJ, et al. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur J Pharmacol. 2009 Nov 25;623(1-3):148-54. doi: 10.1016/j.ejphar.2009.09.027.

Furuta Y, Horiguchi M, Sugaru E, et al. Chronic administration of DSP-7238, a novel, potent, specifi c and substrate-selective DPP IV inhibitor, improves glycaemic control and beta-cell damage in diabetic mice. Diabetes Obes Metab. 2010 May;12(5):421-30. doi: 10.1111/j.1463-1326.2009.01180.x.

Shah P, Ardestani A, Dharmadhikari G, et al. The DPP-4 inhibitor linagliptin restores beta-cell function and survival in human isolated islets through GLP-1 stabilization. J Clin Endocrinol Metab. 2013 Jul;98(7):E1163-72. doi: 10.1210/jc.2013-1029.

Indovina F, Falcetta P, Del Prato S. Type 2 diabetes mellitus. From the start – combination therapy. Diabetes Mellitus. 2018;21(5):386-394. doi: 10.14341/DM9867. (in Russian).

van Raalte DH, Verchere CB. Glucagon-like peptide-1 receptor agonists: beta-cell protection or exhaustion? Trends Endocrinol Metab. 2016 Jul;27(7):442-445. doi: 10.1016/j.tem.2016.04.009.

Inoue K, Maeda N, Fujishima Y, et al. Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study. Diabetol Metab Syndr. 2014 Sep 8;6(1):95. doi: 10.1186/1758-5996-6-95.

Ponzani P. Long-term effectiveness and safety of liraglutide in clinical practice. Minerva Endocrinol. 2013 Mar;38(1):103-12.

Philis-Tsimikas A, Wysham CH, Hardy E, Han J, Iqbal N. Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study. J Diabetes Complications. 2019 Mar;33(3):223-230. doi: 10.1016/j.jdiacomp.2018.11.012.

Abdulreda MH, Rodriguez-Diaz R, Caicedo A, Berggren PO. Liraglutide Compromises Pancreatic β Cell Function in a Humanized Mouse Model. Cell Metab. 2016 Mar 8;23(3):541-6. doi: 10.1016/j.cmet.2016.01.009.

Aston-Mourney K, Hull RL, Zraika S, Udayasankar J, Subramanian SL, Kahn SE. Exendin-4 increases islet amyloid deposition but offsets the resultant beta cell toxicity in human islet amyloid polypeptide transgenic mouse islets. Diabetologia. 2011 Jul;54(7):1756-65. doi: 10.1007/s00125-011-2143-3.

Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013 Jul;62(7):2595-604. doi: 10.2337/db12-1686.

Scheen AJ. Pharmacological management of type 2 diabetes: what's new in 2017? Expert Rev Clin Pharmacol. 2017 Dec;10(12):1383-1394. doi: 10.1080/17512433.2017.1376652.

Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017 Feb;60(2):215-225. doi: 10.1007/s00125-016-4157-3.

Ludvik B, Frías JP, Tinahones FJ, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018 May;6(5):370-381. doi: 10.1016/S2213-8587(18)30023-8.

Brown E, Wilding JPH, Barber TM, Alam U, Cuthbertson DJ. Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. Obes Rev. 2019 Jun;20(6):816-828. doi: 10.1111/obr.12841.

Wysham CH, Pilon D, Ingham M, et al. HbA1c control and cost-effectiveness in patients with type 2 diabetes mellitus initiated on canagliflozin or a glucagon-like peptide 1 receptor agonist in a real-world setting. Endocr Pract. 2018 Mar;24(3):273-287. doi: 10.4158/EP-2017-0066.

Consoli A, Formoso G, Baldassarre MPA, Febo F. A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment. Expert Opin Drug Saf. 2018 Mar;17(3):293-302. doi: 10.1080/14740338.2018.1428305.

Imprialos KP, Stavropoulos K, Stavropoulos N, et al. Sodium-glucose cotransporter 2 inhibitors: Impact on body weight and blood pressure compared with other antidiabetic drugs. Cardiovasc Hematol Disord Drug Targets. 2018;18(2):104-113. doi: 10.2174/1871529X18666180206144342.

Hamamoto H, Noda M. Body weight gain and hyperphagia after administration of SGLT-2 inhibitor: a case report. Am J Case Rep. 2015 Dec 7;16:863-7. doi: 10.12659/ajcr.896233.

Dedov II, Shestakov MV, Aleksandrov AA, et al. Complication of diabetes mellitus: treatment and prevention. Moscow: MIA, 2017. (in Russian).

Cintra R, Moura FA, Carvalho LSF, et al. Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy. Rev Assoc Med Bras (1992). 2019 Jan;65(1):70-86. doi: 10.1590/1806-9282.65.1.70.

Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf. 2019 Apr;18(4):295-311. doi: 10.1080/14740338.2019.1602116.

Scheen AJ. The safety of empagliflozin plus metformin for the treatment of type 2 diabetes. Expert Opin Drug Saf. 2018 Aug;17(8):837-848. doi: 10.1080/14740338.2018.1497159.

Paneni F, Luscher TF. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. Am J Med. 2017 Jun;130(6S):S18-S29. doi: 10.1016/j.amjmed.2017.04.008.

Verges B, Charbonnel B. After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists? Diabetes Metab. 2017 Apr;43 Suppl 1:2S3-2S12. doi: 10.1016/S1262-3636(17)30067-8.

Hussein H, Zaccardi F, Khunti K, Seidu S, Davies MJ, Gray LJ. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis. Diabet Med. 2019 Apr;36(4):444-452. doi: 10.1111/dme.13898.

Scheen AJ. GLP-1 receptor agonists and heart failure in diabetes. Diabetes Metab. 2017 Apr;43 Suppl 1:2S13-2S19. doi: 10.1016/S1262-3636(17)30068-X.

Packer M. Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically Mediated Cardiotoxicity? Clues From Laboratory Models and Clinical Trials. Circ Res. 2018 Mar 30;122(7):928-932. doi: 10.1161/CIRCRESAHA.118.312673.

Ueda P, Svanström H, Melbye M, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363:k4365. doi: 10.1136/bmj.k4365.

Kashiwagi A, Maegawa H. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. J Diabetes Investig. 2017 Jul;8(4):416-427. doi: 10.1111/jdi.12644.

Bonikowska K, Magnusson P, Sjöholm Å. Life-threatening ketoacidosis in patients with type 2 diabetes on LCHF diet. Lakartidningen. 2018 Jun 29;115. pii: E4AD. (in Swedisch).

Brouns F. Overweight and diabetes prevention: is a low-carbohydrate – high-fat diet recommendable? Eur J Nutr. 2018 Jun;57(4):1301-1312. doi: 10.1007/s00394-018-1636-y.

Yabe D, Iwasaki M, Kuwata H, et al. Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study. Diabetes Obes Metab. 2017 May;19(5):739-743. doi: 10.1111/dom.12848.

Yuan Z, DeFalco FJ, Ryan PB, et al. Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study. Diabetes Obes Metab. 2018 Mar;20(3):582-589. doi: 10.1111/dom.13115.

Ryan PB, Buse JB, Schuemie MJ, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab. 2018 Nov;20(11):2585-2597. doi: 10.1111/dom.13424.

Inzucchi SE, Iliev H, Pfarr E, Zinman B. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care. 2018 Jan;41(1):e4-e5. doi: 10.2337/dc17-1551.

Fadini GP, Avogaro A. SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol. 2017 Sep;5(9):680-681. doi: 10.1016/S2213-8587(17)30257-7.

Morgunova T, Fadeev V. Treatment of type 2 diabetes: the stability of the effectiveness of hypoglycemic medications. Obesity and metabolism. 2016;13(3):32-36. doi: 10.14341/omet2016332-36. (in Russian).

Levine JA, Kaihara KA, Layden BT, Wicksteed B. Long-term activation of PKA in β-cells provides sustained improvement to glucose control, insulin sensitivity and body weight. Islets. 2016 Sep 2;8(5):125-34. doi: 10.1080/19382014.2016.1198457.

Nichols CG, Remedi MS. The diabetic β-cell: hyperstimulated vs. hyperexcited. Diabetes Obes Metab. 2012 Oct;14 Suppl 3:129-35. doi: 10.1111/j.1463-1326.2012.01655.x.

Salvi R, Abderrahmani A. Decompensation of β-cells in diabetes: when pancreatic β-cells are on ICE(R). J Diabetes Res. 2014;2014:768024. doi: 10.1155/2014/768024.

Saisho Y. Importance of beta cell function for the treatment of type 2 diabetes. J Clin Med. 2014 Aug 14;3(3):923-43. doi: 10.3390/jcm3030923.

Jargin SV. Recent advances in management of type 2 diabetes mellitus with obesity. Lechashchii Vrach. 2019;(4):84-86. (in Russian).

Jargin SV. Management of type 2 diabetes mellitus with overweight: Focus on SGLT-2 inhibitors and GLP-1 receptor agonists. Eur J Ther. 2019;25:93-96. doi: 10.5152/EurJTher.2019.18067.

DiNicolantonio JJ, Bhutani J, O’Keefe JH. Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. Open Heart. 2015 Oct 19;2(1):e000327. doi: 10.1136/openhrt-2015-000327.

van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care. 2005 Jan;28(1):154-63. doi: 10.2337/diacare.28.1.154.

Gross JL, Kramer CK, Leitão CB, et al. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med. 2011 May 17;154(10):672-9. doi: 10.7326/0003-4819-154-10-201105170-00007.

Schnell O, Weng J, Sheu WH, et al. Acarbose reduces body weight irrespective of glycemic control in patients with diabetes: results of a worldwide, non-interventional, observational study data pool. J Diabetes Complications. 2016 May-Jun;30(4):628-37. doi: 10.1016/j.jdiacomp.2016.01.023.

Gendeleka GF, Gendeleka AN. Preventive diabetology at the turn of the centuries. Prevention of type 2 diabetes mellitus: achievements and prospects. Mìžnarodnij endokrinologìčnij žurnal. 2019;15(2):178-185. doi: 10.22141/2224-0721.15.2.2019.166112. (in Russian).

Esquivel MA, Lansang MC. Optimizing diabetes treatment in the presence of obesity. Cleve Clin J Med. 2017 Jul;84(7 Suppl 1):S22-S29. doi: 10.3949/ccjm.84.s1.04.

Pankiv ІV. Step-by-step individual intensification of therapy for type 2 diabetes mellitus: What is further choice after metformin? Mìžnarodnij endokrinologìčnij žurnal. 2015;(66):89-94. doi: 10.22141/2224-0721.2.66.2015.75447. (in Ukrainian).

Zonszein J, Groop PH. Strategies for diabetes management: using newer oral combination therapies early in the disease. Diabetes Ther. 2016 Dec;7(4):621-639. doi: 10.1007/s13300-016-0208-5.

Ametov AS, Prudnikova MA. The role of drugs for weight reduction in stages management of type 2 diabetes: focus on sibutramine. Endocrinology. 2017;(1):52-59. (in Russian).

Le Fanu J. Mass medicalisation is an iatrogenic catastrophe. BMJ. 2018 Jun 28;361:k2794. doi: 10.1136/bmj.k2794.

Jargin SV. Scientific papers and patents on substances with unproven effects. Recent Pat Drug Deliv Formul. 2019;13(1):37-45. doi: 10.2174/1872211313666190307162041.

Gendeleka GF, Gendeleka AN. Typical mistakes in the diagnosis and treatment of diabetes mellitus. Mìžnarodnij endokrinologìčnij žurnal. 2017;13(3):191-196. doi: 10.22141/2224-0721.13.3.2017.104118. (in Russian).

Dedov II. Diabetes mellitus – a dangerous treat to the mankind. Vestn Ross Akad Med Nauk. 2012;(1):7-13. (in Russian).

Makam AN, Nguyen OK. An evidence-based medicine approach to antihyperglycemic therapy in diabetes mellitus to overcome overtreatment. Circulation. 2017 Jan 10;135(2):180-195. doi: 10.1161/CIRCULATIONAHA.116.022622.

Lipska KJ, Ross JS, Miao Y, Shah ND, Lee SJ, Steinman MA. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med. 2015 Mar;175(3):356-62. doi: 10.1001/jamainternmed.2014.7345.

Weiss IA, Valiquette G, Schwarcz MD. Impact of glycemic treatment choices on cardiovascular complications in type 2 diabetes. Cardiol Rev. 2009 Jul-Aug;17(4):165-75. doi: 10.1097/CRD.0b013e3181a7b34c.

Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 Jan 8;360(2):129-39. doi: 10.1056/NEJMoa0808431.

Andersson C, van Gaal L, Caterson ID, et al. Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. Diabetologia. 2012 Sep;55(9):2348-55. doi: 10.1007/s00125-012-2584-3.

ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2560-72. doi: 10.1056/NEJMoa0802987.

Paul SK, Klein K, Thorsted BL, et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:100.

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577-89. doi: 10.1056/NEJMoa0806470.

Vaag AA. Glycemic control and prevention of microvascular and macrovascular disease in the Steno 2 study. Endocr Pract. 2006 Jan-Feb;12 Suppl 1:89-92. doi: 10.4158/EP.12.S1.89.

Rawshani A, Rawshani A, Franzen S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2018; 379:633-644. doi: 10.1056/NEJMoa1800256.

Chatterjee S, Khunti K, Davies MJ. Optimizing management of glycaemia. Best Pract Res Clin Endocrinol Metab. 2016 Jun;30(3):397-411. doi: 10.1016/j.beem.2016.06.002.

Rodriguez-Gutierrez R, Montori VM. Glycemic control for patients with type 2 diabetes mellitus: Our evolving faith in the face of evidence. Circ Cardiovasc Qual Outcomes. 2016 Sep;9(5):504-12. doi: 10.1161/CIRCOUTCOMES.116.002901.

Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743.

Laakso M, Cederberg H. Glucose control in diabetes: which target level to aim for? J Intern Med. 2012 Jul;272(1):1-12. doi: 10.1111/j.1365-2796.2012.02528.x.

Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011 Jul 26;343:d4169. doi: 10.1136/bmj.d4169.

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998 Sep 12;352(9131):854-65.

Galstian GR. The concervator’s viewpoint. Effective Pharmacotherapy. 2018;(12):52-53. (in Russian).

Avogaro A, Fadini GP, Sesti G, Bonora E, Del Prato S. Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. Cardiovasc Diabetol. 2016 Aug 11;15(1):111. doi: 10.1186/s12933-016-0431-4.

Hayward RA, Reaven PD, Wiitala WL, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015 Jun 4;372(23):2197-206. doi: 10.1056/NEJMoa1414266.

Wong MG, Perkovic V, Chalmers J, et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care. 2016 May;39(5):694-700. doi: 10.2337/dc15-2322.

Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010 Aug 7;376(9739):419-30. doi: 10.1016/S0140-6736(10)60576-4.

Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014 Oct 9;371(15):1392-406. doi: 10.1056/NEJMoa1407963.

Montori VM, Fernandez-Balsells M. Glycemic control in type 2 diabetes: time for an evidence-based about-face? Ann Intern Med. 2009 Jun 2;150(11):803-8. doi: 10.7326/0003-4819-150-11-200906020-00008.

Kim KB, Kim MT, Ko JS. Excess insulin and hypoxia, linkages to obesity and type 2 diabetes. Integr Obesity Diabetes. 2018;4(2):1-6. doi: 10.15761/IOD.1000204.

Erion KA, Corkey BE. Hyperinsulinemia: a cause of obesity? Curr Obes Rep. 2017 Jun;6(2):178-186. doi: 10.1007/s13679-017-0261-z.

Al Mansari A, Obeid Y, Islam N, et al. GOAL study: clinical and non-clinical predictive factors for achieving glycemic control in people with type 2 diabetes in real clinical practice. BMJ Open Diabetes Res Care. 2018 Jul 10;6(1):e000519. doi: 10.1136/bmjdrc-2018-000519.